146 related articles for article (PubMed ID: 10537061)
1. Tissue transglutaminase is increased in Huntington's disease brain.
Lesort M; Chun W; Johnson GV; Ferrante RJ
J Neurochem; 1999 Nov; 73(5):2018-27. PubMed ID: 10537061
[TBL] [Abstract][Full Text] [Related]
2. 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease.
Mastroberardino PG; Iannicola C; Nardacci R; Bernassola F; De Laurenzi V; Melino G; Moreno S; Pavone F; Oliverio S; Fesus L; Piacentini M
Cell Death Differ; 2002 Sep; 9(9):873-80. PubMed ID: 12181738
[TBL] [Abstract][Full Text] [Related]
3. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients.
Richfield EK; Maguire-Zeiss KA; Vonkeman HE; Voorn P
Ann Neurol; 1995 Dec; 38(6):852-61. PubMed ID: 8526457
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase cross-links in intranuclear inclusions in Huntington disease.
Zainelli GM; Ross CA; Troncoso JC; Muma NA
J Neuropathol Exp Neurol; 2003 Jan; 62(1):14-24. PubMed ID: 12528814
[TBL] [Abstract][Full Text] [Related]
5. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease.
Guidetti P; Luthi-Carter RE; Augood SJ; Schwarcz R
Neurobiol Dis; 2004 Dec; 17(3):455-61. PubMed ID: 15571981
[TBL] [Abstract][Full Text] [Related]
6. Striatal interneurons in Huntington's disease: selective increase in the density of calretinin-immunoreactive medium-sized neurons.
Cicchetti F; Parent A
Mov Disord; 1996 Nov; 11(6):619-26. PubMed ID: 8914086
[TBL] [Abstract][Full Text] [Related]
7. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms.
Bailey CD; Johnson GV
J Neurochem; 2005 Jan; 92(1):83-92. PubMed ID: 15606898
[TBL] [Abstract][Full Text] [Related]
8. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells.
Chun W; Lesort M; Tucholski J; Faber PW; MacDonald ME; Ross CA; Johnson GV
Neurobiol Dis; 2001 Jun; 8(3):391-404. PubMed ID: 11442349
[TBL] [Abstract][Full Text] [Related]
9. Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3.
Zainelli GM; Dudek NL; Ross CA; Kim SY; Muma NA
J Neuropathol Exp Neurol; 2005 Jan; 64(1):58-65. PubMed ID: 15715085
[TBL] [Abstract][Full Text] [Related]
10. Selective neuronal degeneration in Huntington's disease.
Cowan CM; Raymond LA
Curr Top Dev Biol; 2006; 75():25-71. PubMed ID: 16984809
[TBL] [Abstract][Full Text] [Related]
11. Calmodulin regulates transglutaminase 2 cross-linking of huntingtin.
Zainelli GM; Ross CA; Troncoso JC; Fitzgerald JK; Muma NA
J Neurosci; 2004 Feb; 24(8):1954-61. PubMed ID: 14985437
[TBL] [Abstract][Full Text] [Related]
12. The fate of the large striatal interneurons expressing calretinin in Huntington's disease.
Massouh M; Wallman MJ; Pourcher E; Parent A
Neurosci Res; 2008 Dec; 62(4):216-24. PubMed ID: 18801393
[TBL] [Abstract][Full Text] [Related]
13. Huntington aggregates may not predict neuronal death in Huntington's disease.
Kuemmerle S; Gutekunst CA; Klein AM; Li XJ; Li SH; Beal MF; Hersch SM; Ferrante RJ
Ann Neurol; 1999 Dec; 46(6):842-9. PubMed ID: 10589536
[TBL] [Abstract][Full Text] [Related]
14. Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease.
Giampà C; DeMarch Z; D'Angelo V; Morello M; Martorana A; Sancesario G; Bernardi G; Fusco FR
Eur J Neurosci; 2006 Jan; 23(1):11-20. PubMed ID: 16420411
[TBL] [Abstract][Full Text] [Related]
15. Double-strand RNA dependent protein kinase (PKR) is involved in the extrastriatal degeneration in Parkinson's disease and Huntington's disease.
Bando Y; Onuki R; Katayama T; Manabe T; Kudo T; Taira K; Tohyama M
Neurochem Int; 2005 Jan; 46(1):11-8. PubMed ID: 15567511
[TBL] [Abstract][Full Text] [Related]
16. Does tissue transglutaminase play a role in Huntington's disease?
Lesort M; Chun W; Tucholski J; Johnson GV
Neurochem Int; 2002 Jan; 40(1):37-52. PubMed ID: 11738471
[TBL] [Abstract][Full Text] [Related]
17. Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates.
Chun W; Lesort M; Tucholski J; Ross CA; Johnson GV
J Cell Biol; 2001 Apr; 153(1):25-34. PubMed ID: 11285271
[TBL] [Abstract][Full Text] [Related]
18. Neurofilament and neural cell adhesion molecule immunocytochemistry of Huntington's disease striatum.
Nihei K; Kowall NW
Ann Neurol; 1992 Jan; 31(1):59-63. PubMed ID: 1531909
[TBL] [Abstract][Full Text] [Related]
19. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease.
Singhrao SK; Neal JW; Morgan BP; Gasque P
Exp Neurol; 1999 Oct; 159(2):362-76. PubMed ID: 10506508
[TBL] [Abstract][Full Text] [Related]
20. Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei.
Karpuj MV; Garren H; Slunt H; Price DL; Gusella J; Becher MW; Steinman L
Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7388-93. PubMed ID: 10377424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
